Pharmacokinetics of morphine infusion in premature neonates

R Hartley, M Green, M Quinn, M I Levene

Abstract

Morphine pharmacokinetics were studied in 17 premature neonates (26–34 weeks' gestation) after intravenous infusion during the first 24 hours of life. Infants received either standard dose morphine that comprised of a 100 µg/kg/hour loading infusion for 2 hours followed by a maintenance infusion of 12.5 µg/kg/hour, or a high dose of 200 µg/kg/hour for 2 hours followed by 50 µg/kg/hour. Mean plasma concentrations of morphine (SD) after 2 and 24 hours were 99 (12.9) and 96.4 (3.2) ng/ml, and 184.2 (37.7) and 319 (71.2) ng/ml for the standard and high dose regimens, respectively. Morphine-3-glucuronide plasma concentrations achieved about 20% and 80% of morphine values at 2 and 24 hours respectively. Morphine-6-glucuronide could not be detected at 2 hours, but attained 20–25% of morphine plasma concentrations by 24 hours. The population mean morphine clearance was 2.4 ml/min/kg, the elimination half life was 8.75 hours and the volume of distribution was 1.82 l/kg. High plasma concentrations of morphine appeared to be well tolerated. Although mean arterial blood pressure decreased during the first six hours of treatment, this was not statistically significant; two infants experienced transient muscle rigidity, but no evidence of seizures was noted. There appears to be no clinical advantage in using the high dose regimen. (Arch Dis Child 1993; 69: 55–58)

Morphine is increasingly used as a sedative and analgesic in neonatal intensive care, particularly for the management of infants requiring mechanical ventilation during treatment of respiratory distress syndrome.¹ Unfortunately, 25% of premature neonates continue to 'fight' the ventilator, despite relatively high doses of morphine² and may require pancuronium to inhibit these spontaneous respirations.³ However, treatment with morphine may be preferential to pancuronium in reducing the stress of intensive care in preterm infants.²

The safe and effective use of morphine in premature neonates is complicated by the presence of active metabolites. Morphine-6-glucuronide (M6G) is a potent analgesic⁴ and respiratory depressant,⁵ while morphine-3-glucuronide (M3G) antagonises the analgesic effects of both morphine and M6G,^{6,7} and stimulates respiratory activity.⁸ Preterm infants can metabolise morphine by glucuronidation, but M3G:morphine plasma concentration ratios suggest that their metabolic capacity is

reduced in comparison with children aged 1–16 years.⁹ Recent studies in premature neonates have also indicated developmental changes in the half life ($t_{1/2}$)^{10–12} and plasma clearance of morphine.^{11,12} The reduced capacity for conversion of morphine to M6G in premature neonates may compromise the efficacy of the drug within this patient group. Alternatively, the delay in clinical response may be due to inadequate plasma concentrations of morphine during the first 2–4 hours of treatment. The increased risk of serious lung and brain complications in premature infants who actively expire against positive pressure inflation^{3,13} prompted us to administer a loading dose of morphine as an intravenous infusion, followed by a constant rate infusion to provide effective plasma concentrations more rapidly, and to evaluate increases in dose rate. This study investigates the pharmacokinetics of the drug and disposition of its glucuronide metabolites in premature neonates (gestational age 26–34 weeks), who had received the standard or high dose regimen during the first 24 hours of life (postnatal age <24 hours at initiation of treatment).

Patients and methods

PATIENTS

Plasma concentrations of morphine were investigated in 17 premature neonates (nine boys) during the first 24 hours of treatment in order to provide population estimates of plasma clearance, $t_{1/2}$, and volume of distribution. Infants' gestational age ranged from 26–34 weeks (mean (SD) 29.6 (2.03) weeks) postnatal age (on entry into the study) was <1 day in all cases, and birth weight ranged from 900 to 2260 g (mean (SD) 1330 (380) g). Details of individual patients are shown in table 1. All infants had respiratory distress syndrome and were receiving morphine intravenously to encourage synchronisation of their respiratory effort with the ventilator, as well as for analgesia.

DOSAGE REGIMENS

Two dosage regimens were used: standard dose morphine that comprised a 100 µg/kg/hour loading infusion for 2 hours, followed by a maintenance infusion of 12.5 µg/kg/hour and high dose that consisted of a 200 µg/kg/hour loading infusion for 2 hours, followed by a constant rate infusion of 50 µg/kg/hour. The study was approved by the Leeds West Hospital ethics committee and informed parental consent was obtained before starting the infusion. Blood was obtained via an umbilical arterial catheter after 0, 2, 4, 6, 12, and 24 hours of morphine treatment; however, only four

Academic Unit of Paediatrics and Child Health, Department of Clinical Medicine, University of Leeds, D Floor, Clarendon Wing, Leeds General Infirmary, Belmont Grove, Leeds LS2 9NS
R Hartley
M Green
M Quinn
M I Levene

Correspondence to:
Dr Hartley.

Accepted 20 March 1993

Table 1 Clinical details, plasma concentrations of morphine and plasma clearance

Patient No	Sex	Birth weight (g)	Gestation (weeks)	Dose regimen (μg/kg/hour)	Plasma concentration (ng/ml)		Clearance (ml/min/kg)
					2 hours	24 hours	
Standard dose							
1	F	1000	28	100*/12.5†	106	—	—
2	F	1010	29	100/12.5	103	96	2.17
3	F	2260	34	100/12.5	99	—	—
4	M	1320	29	100/12.5	110	—	—
5	M	1080	26	100/12.5	77	—	—
6	M	910	31	100/12.5	—	93	2.24
7	F	1260	28	100/12.5	—	94	2.22
8	F	1340	31	100/12.5	—	98	2.13
9	M	1240	28	100/12.5	—	101	2.06
Mean (SD)		1270 (400)	29.3 (2.3)		99.0 (12.9)	96.4 (3.2)	2.16 (0.1)
High dose							
10	F	960	27	200/50	128	—	—
11	F	900	27	200/50	194	—	—
12	M	1700	31	200/50	161	298	2.80
13	M	1720	31	200/50	200	298	2.80
14	F	1350	31	200/50	141	258	3.23
15	M	1680	31	200/50	203	—	—
16	M	1800	31	200/50	206	—	—
17	M	1460	29	200/50	241	422	1.97
Mean (SD)		1450 (400)	29.8 (1.8)		184.2 (37.7)	319 (71.2)	2.70 (0.5)

*2 hour loading infusion; †constant rate infusion.

samples were taken from any one baby (approximately 0.6 ml per sample) to minimise the blood volume requirement per patient. Plasma was separated and stored at -70°C before analysis.

CLINICAL OBSERVATIONS

All infants received regular monitoring of blood pressure, heart rate, respiratory rate, blood gases, ventilator rate, and blood glucose. Infants receiving the high dose regimen, however, had their blood pressure continuously monitored via an umbilical arterial catheter, for at least six hours after commencement of morphine infusion, and these babies were closely observed for evidence of seizures during the first 24 hours.

ANALYTICAL METHODS

Morphine, M3G, and M6G were measured in plasma using a reversed phase ion pair high performance liquid chromatographic method specifically developed for this study.¹⁴

PHARMACOKINETIC CALCULATIONS

An estimate of the population mean plasma clearance was obtained by dividing the morphine infusion rate by the apparent steady state plasma concentration of morphine after 24 hours of treatment. This population mean plasma clearance (Clp) value was used to simulate plasma concentration-time profiles for a range of $t_{1/2}$ values (8–9 hours), using standard pharmacokinetic calculations,¹⁵ equations (1) and (2), for determining the plasma concentration at steady state (C_{ss}) and the plasma concentration at time t (C), after a constant rate infusion

$$C_{ss} = \text{infusion rate} / \text{Clp} \quad (1)$$

$$C = C_{ss} [1 - (1/2)^n] \quad (2)$$

where n is expressed in multiples of the $t_{1/2}$ of the drug (that is n is the time t divided by $t_{1/2}$). An estimate of the population mean $t_{1/2}$ was subsequently obtained by superimposing mean (SE) measured plasma concentrations of

morphine in samples from premature neonates (at 2, 4, 6, 12, and 24 hours for the standard dose, and 2 and 24 hours for the high dose regimens, respectively) onto these simulated plasma concentration-time curves, and examining for 'best fit'. The population mean volume of distribution (Vd) was calculated from estimates of plasma clearance and $t_{1/2}$ thus obtained, using equation (3)

$$Vd = \text{Clp} \times t_{1/2} / 0.693 \quad (3)$$

STATISTICAL ANALYSIS

Results are given as mean (SD). The difference between mean plasma clearance values for the standard and high dose regimens, and changes in mean arterial blood pressure, were assessed by the Mann-Whitney U test. Relationships between birth weight or gestational age and plasma clearance were investigated using Spearman's rank correlation analysis. A p value of <0.05 was considered to be statistically significant.

Results

PLASMA CONCENTRATIONS

Morphine was detected in all plasma samples obtained from 2 hours through to 24 hours, irrespective of dosage regimen (figure). Mean (SD) plasma concentrations were 99 (12.9), 110 (39.6), 104 (32.6), 108 (35.4), and 96.4 (3.2) ng/ml for the standard dose regimen at 2, 4, 6, 12, and 24 hours, respectively; mean (SD) values for the high dose regimen were 184.2 (37.7) and 319 (71.2) ng/ml at 2 and 24 hours, respectively. M3G could be measured in all samples obtained at 2 hours and 24 hours, mean (SD) plasma concentrations were 20.7 (7.6) and 33.3 (14.3) ng/ml at 2 hours, and 61.8 (33.7) and 273.5 (71.4) ng/ml at 24 hours, for the standard and high dose regimens, respectively. In contrast, plasma concentrations of M6G could not be detected in samples obtained at 2 hours, irrespective of dose, but were measured in 24 hour samples (mean (SD) 19.2 (6.7) and 78 (23.8) ng/ml for the standard and high dose regimens, respectively).

Mean (SE) plasma concentrations of morphine measured in samples obtained from premature neonates (at 2, 4, 6, 12 and 24 hours, and 2 and 24 hours for the standard and high dose regimens, respectively) superimposed on simulated plasma concentration-time profiles, based on the population mean plasma clearance (2.4 ml/min/kg) and half life ($t_{1/2}$) values of 8, 8.5, 8.75, and 9 hours for the two dose regimens. Visual examination for 'best fit' between mean measured values and simulated data for the standard dose (A) and high dose (B) regimens, indicates a population mean $t_{1/2}$ close to 8.75 hours.

PHARMACOKINETICS

Plasma clearance values for individual patients, derived from 24 hour morphine plasma concentrations, are shown in table 1. The difference between mean plasma clearance values for the standard and high dose regimens was not statistically significant. Trends suggesting an increase in the clearance of morphine with increasing birth weight and gestational age were observed, but these did not achieve significance ($r=0.310$ and 0.630 , respectively; nine data pairs, $p>0.05$). The population mean clearance of morphine was 2.4 ml/min/kg ($n=9$). The population mean

$t_{1/2}$ for morphine was found to be 8.75 hours. This value provided the 'best fit' when mean (SE) measured plasma concentrations of morphine were superimposed on simulated plasma concentration-time profiles (using $t_{1/2}$ values from 8–9 hours) for the standard and high dose regimens (figure). The population mean volume of distribution derived from these two pharmacokinetic parameters was 1.82 l/kg.

CLINICAL OBSERVATIONS

Mean arterial blood pressure data from seven infants receiving the high dose regimen are presented in table 2. Although mean blood pressure decreased between 6.4–10.7% during the first 6 hours of morphine infusion, these changes were not statistically significant ($p>0.05$); the largest decrease noted after 2 hours coincided with the completion of the loading infusion. Despite careful observation, there was no indication of seizures during the first 24 hours, but we did note transient hypertonia in two infants.

Discussion

The need for multiple samples in pharmacokinetic studies involving premature neonates can present a problem. Clearly, the volume of blood that can justifiably be obtained from acutely ill preterm infants is limited, particularly in the first 24 hours of treatment. The approach outlined in this study, using simulation techniques, provides a way of obtaining population estimates of pharmacokinetic parameters and minimises the sample requirement to only four samples per infant. The population mean morphine plasma clearance of 2.4 ml/min/kg is slightly lower than previously published values of 4.7, 3.39, and 3.6 ml/min/kg in preterm infants,^{9 11 12} but this may be due to differences in postnatal age between the present (<1 day) and earlier study populations (>2 days). Morphine plasma clearance showed a tendency to increase with birth weight and gestational age; though not statistically significant, these trends reflect the developmental changes in morphine clearance reported by Bhat *et al*¹¹ and Barrett *et al*.¹² Mean plasma clearance values for the standard and high dose regimens were not significantly different, supporting the view that the metabolism of morphine is not dose dependent.¹⁶ The population mean $t_{1/2}$ for morphine of 8.75 hours is in good agreement with values of 10.3, 10, and 8.9 hours reported for premature neonates.^{10–12} All of these earlier studies noted a decrease in morphine half life with increasing postconceptional or gestational age. The population mean volume of distribution of 1.82 l/kg concurs with published values of 1.84 and 2.7 l/kg^{11 12}; this range of values may also reflect differences in postnatal age between study populations.

Mean morphine plasma concentrations measured in samples obtained at 2 and 24 hours (99.0 and 96.4 ng/ml, respectively), from infants receiving the standard dose regimen, are in good agreement with the predicted steady state concentration (86.8 ng/ml) derived from the population mean plasma

Table 2 Mean arterial blood pressure (mm Hg) in infants receiving the high dose regimen

Patient No	Duration of morphine infusion (hours)						
	0	1	2	3	4	5	6
1	32	28	30	36	33	35	35
2	52	50	47	47	47	43	45
3	51	40	38	40	41	36	39
4	39	35	30	30	30	30	31
5	36	32	34	38	38	39	39
6	43	45	42	43	43	42	39
7	42	43	42	42	41	40	40
Mean (SD)	42.1(7.4)	39.0(7.8)	37.6(6.5)	39.4(5.5)	39.0(5.9)	37.9(4.5)	38.3(4.4)
% Decrease	–	7.4	10.7	6.4	7.4	10.0	9.0

clearance (2.4 ml/min/kg); this suggests that steady state plasma concentrations are achieved rapidly and within 2 hours. For the high dose regimen, the mean measured morphine plasma concentration at 24 hours (319 ng/ml) indicates that this regimen achieves about 92% of the predicted steady state plasma concentration (347.2 ng/ml) by this time.

The mean plasma morphine concentrations obtained after a 2 hour loading infusion (99.0 and 184.2 ng/ml for the standard and high dose regimens, respectively), exceed the reported minimum concentrations required for analgesia in children.¹⁷ On this basis, both dosage regimens appear to produce effective plasma concentrations of morphine within 2 hours. The plasma concentrations of morphine necessary to ensure adequate analgesia, and/or to suppress spontaneous respirations, in premature neonates remain unclear. Developmental changes in the pharmacokinetics of morphine¹⁰⁻¹² imply that for a given dose, preterm infants will achieve a higher plasma concentration of morphine for a longer duration than full term neonates or older babies. It has been suggested that young infants are particularly sensitive to respiratory depression.¹⁸ Though an undesirable side effect in unventilated infants, respiratory depression is potentially beneficial in preventing the baby breathing out of synchrony with the ventilator in infants with respiratory distress syndrome. Despite efforts to optimise morphine dosage regimens by ensuring adequate plasma concentrations of morphine within 2 hours, 25% of premature neonates continue to fight the ventilator. As the glucuronides have been shown to have opposing effects on respiratory effort (M6G is a respiratory depressant⁵ while M3G has been shown to be a respiratory stimulant⁸), the relative plasma concentrations of M3G and M6G may be important. It is of interest that at the time pancuronium is added to inhibit spontaneous respirations (usually within 2-4 hours), plasma concentrations of M6G after morphine infusion are virtually undetectable in premature neonates, irrespective of dose, whereas M3G plasma concentrations achieve about 20-30% of morphine plasma concentrations. This imbalance in plasma concentrations of the active metabolites may be the reason that some preterm infants continue to struggle against the ventilator. Alternatively, the variability in clinical response could be due to differences in the development of opiate receptors or the permeability of the blood-brain barrier.

The relatively high morphine plasma concentrations resulting from the high dose regimen (182.4 and 319 ng/ml at 2 and 24 hours, respectively) were well tolerated. Mean blood pressure decreased during the first six hours, the maximum change (10.7%) was noted at 2 hours corresponding with completion of the loading infusion. However, the changes in mean blood pressure were not

statistically significant and were not associated with clinical deterioration. Indeed, although we have data from only seven infants, these changes may reflect a transition from higher blood pressure values in stressed babies to more normal values as the sedative and analgesic effects of morphine settle the infants. Giving the loading dose over 2 hours appears to alleviate concern regarding reductions in blood pressure when opioid drugs are given as an intravenous bolus.¹⁹ Despite careful clinical observation, we found no evidence to support the view that high plasma morphine concentrations are associated with seizures.²⁰ We did note transient hypertonia in two infants but this did not necessitate termination of the morphine infusion. As clinical effect seems to be unaffected by dosage increment, there appears to be no advantage in using the high dose regimen.

- 1 Elias-Jones AC, Barrett DA, Rutter N, Shaw PN, Davis SS. Diamorphine infusion in the preterm infant. *Arch Dis Child* 1991; **66**: 1155-7.
- 2 Quinn MW, Otoo F, Rushforth JA, et al. Effect of morphine and pancuronium on the stress response in ventilated preterm infants. *Early Hum Dev* 1992; **30**: 241-8.
- 3 Greenough A, Morley CJ, Wood S, Davis JA. Pancuronium prevents pneumothoraces in ventilated premature babies who actively expire against positive pressure inflation. *Lancet* 1984; **i**: 1-3.
- 4 Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behaviour after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. *Clin Pharmacol Ther* 1990; **47**: 12-9.
- 5 Hasselstrom J, Berg U, Lofgren A, Sawe J. Long lasting respiratory depression induced by morphine-6-glucuronide? *Br J Clin Pharmacol* 1989; **27**: 515-8.
- 6 Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide - a potent antagonist of morphine analgesia. *Life Sci* 1990; **47**: 579-85.
- 7 Watt JA, Cramond T, Smith MT. Morphine-6-glucuronide: analgesic effects antagonized by morphine-3-glucuronide. *Clin Exp Pharmacol Physiol* 1990; **17** suppl: 83.
- 8 Gong Q-L, Hedner T, Hedner J, Bjorkman R, Nordberg G. Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. *Eur J Pharmacol* 1991; **193**: 47-56.
- 9 Choonara IA, McKay P, Hain R, Rane A. Morphine metabolism in children. *Br J Clin Pharmacol* 1989; **28**: 599-604.
- 10 Mercurio M, Nelli C, Gettner P, Sherwonit E, Williams J, Ehrenkranz R. Morphine pharmacokinetics in premature newborns. *Pediatr Res* 1989; **25** (71A): A408.
- 11 Bhat R, Chari G, Gulati A, Aldana O, Velamati R, Bhargava H. Pharmacokinetics of a single dose of morphine in preterm infants during the first week of life. *J Pediatr* 1990; **117**: 477-81.
- 12 Barrett DA, Elias-Jones AC, Rutter N, Shaw PN, Davis SS. Morphine kinetics after diamorphine infusion in premature neonates. *Br J Clin Pharmacol* 1991; **32**: 31-7.
- 13 Perlman JM, Goodman S, Kreusser KL, Volpe JJ. Reduction in intraventricular hemorrhage by elimination of fluctuating cerebral blood-flow velocity in preterm infants with respiratory distress syndrome. *N Engl J Med* 1985; **312**: 1353-7.
- 14 Hartley R, Green M, Quinn M, Levene MI. Analysis of morphine and its 3- and 6-glucuronides by high performance liquid chromatography with fluorometric detection following solid phase extraction from neonatal plasma. *Biomed Chromatogr* 1993; **7**: 34-7.
- 15 Rowland M, Tozer TN. *Clinical pharmacokinetics: concepts and applications*. 2nd Ed. Philadelphia: Lea and Febiger, 1989.
- 16 Sawe J, Svensson JO, Rane A. Morphine metabolism in cancer patients on increasing oral doses - no evidence for autoinduction or dose-dependence. *Br J Clin Pharmacol* 1983; **16**: 85-93.
- 17 Dahlstrom B, Bolin P, Feychting H, Noack G, Paalzour L. Morphine kinetics in children. *Clin Pharmacol Ther* 1979; **26**: 354-65.
- 18 Lynn AM, Slattery JT. Morphine pharmacokinetics in early infancy. *Anesthesiology* 1987; **66**: 136-9.
- 19 Marlow N, Windling AM, Cooke RWI. Hazards of analgesia for newborn infants. *Arch Dis Child* 1988; **63**: 1293.
- 20 Koren G, Butt W, Chinyanga H, Soldin S, Tan YK, Pape K. Postoperative morphine infusion in newborn infants: assessment of disposition characteristics and safety. *J Pediatr* 1985; **107**: 963-7.